JP2015505550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505550A5 JP2015505550A5 JP2014555197A JP2014555197A JP2015505550A5 JP 2015505550 A5 JP2015505550 A5 JP 2015505550A5 JP 2014555197 A JP2014555197 A JP 2014555197A JP 2014555197 A JP2014555197 A JP 2014555197A JP 2015505550 A5 JP2015505550 A5 JP 2015505550A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- optionally substituted
- pharmaceutically active
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 6
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 229940127218 antiplatelet drug Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 3
- -1 —O-benzyl Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 claims 2
- 108010024976 Asparaginase Proteins 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 2
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical group COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 claims 2
- 229950000285 anacetrapib Drugs 0.000 claims 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 2
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 2
- 229940125753 fibrate Drugs 0.000 claims 2
- 150000002814 niacins Chemical class 0.000 claims 2
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 claims 1
- OCNBSSLDAIWTKS-UHFFFAOYSA-N 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-n,n-bis(cyclopropylmethyl)-8-methylquinolin-2-amine Chemical compound C1CC1CN(CC1CC1)C=1N=C2C(C)=CC=CC2=CC=1CN(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OCNBSSLDAIWTKS-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229950004181 dalcetrapib Drugs 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- IHIUGIVXARLYHP-YBXDKENTSA-N evacetrapib Chemical compound C1([C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC2)=CC(C)=CC(C)=C1N2C[C@H]1CC[C@H](C(O)=O)CC1 IHIUGIVXARLYHP-YBXDKENTSA-N 0.000 claims 1
- 229950000005 evacetrapib Drugs 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- NRWORBQAOQVYBJ-GJZUVCINSA-N obicetrapib Chemical compound N=1C=C(OCCCC(O)=O)C=NC=1N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NRWORBQAOQVYBJ-GJZUVCINSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593638P | 2012-02-01 | 2012-02-01 | |
| US61/593,638 | 2012-02-01 | ||
| PCT/EP2013/051871 WO2013113799A1 (en) | 2012-02-01 | 2013-01-31 | Phenyl -c-oxadiazole derivatives as inhibitors of leukotriene production combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505550A JP2015505550A (ja) | 2015-02-23 |
| JP2015505550A5 true JP2015505550A5 (enExample) | 2016-03-24 |
| JP6069771B2 JP6069771B2 (ja) | 2017-02-01 |
Family
ID=47631435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555197A Active JP6069771B2 (ja) | 2012-02-01 | 2013-01-31 | ロイコトリエン生成の阻害薬としてのフェニル−ｃ−オキサジアゾール誘導体併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9248187B2 (enExample) |
| EP (1) | EP2809321B1 (enExample) |
| JP (1) | JP6069771B2 (enExample) |
| AR (1) | AR089853A1 (enExample) |
| TW (1) | TW201343641A (enExample) |
| UY (1) | UY34604A (enExample) |
| WO (1) | WO2013113799A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| BR112015024116A2 (pt) | 2013-03-27 | 2017-10-24 | Hoffmann La Roche | marcadores genéticos para prever capacidade de resposta à terapia |
| JP6854752B2 (ja) | 2014-07-30 | 2021-04-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー |
| CA3102032A1 (en) | 2018-06-05 | 2019-12-12 | Anji Pharma (Us) Llc | Compositions and methods for treating pancreatitis |
| CA3191164A1 (en) * | 2020-08-10 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28 |
| KR102312897B1 (ko) * | 2021-02-26 | 2021-10-15 | 에스케이바이오사이언스(주) | 목적 단백질의 고수율 정제방법 |
| IL291418B2 (en) | 2022-03-16 | 2024-05-01 | Anima Biotech Inc | Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206471B1 (en) | 1999-08-06 | 2006-03-01 | Janssen Pharmaceutica N.V. | Interleukin-5 inhibiting 6-azauracil derivatives |
| US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
| AU2005295646B2 (en) | 2004-10-18 | 2008-11-20 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes as flap inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| EP2013174B1 (en) | 2006-04-11 | 2013-05-08 | Merck Sharp & Dohme Corp. | Diaryl substituted alkanes |
| ES2376396T3 (es) | 2006-06-26 | 2012-03-13 | Amgen Inc. | Método para tratar aterosclerosis. |
| CA2666686A1 (en) * | 2006-09-01 | 2008-03-13 | Merck & Co., Inc. | Inhibitors of 5-lipoxygenase activating protein (flap) |
| WO2008128335A1 (en) | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP2546232A1 (en) | 2007-06-20 | 2013-01-16 | Merck Sharp & Dohme Corp. | Diphenyl Substituted Alkanes |
| AU2008311375A1 (en) | 2007-10-10 | 2009-04-16 | Merck Sharp & Dohme Corp. | Diphenyl substituted cycloalkanes |
| EP2358371B1 (en) | 2008-10-31 | 2015-02-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| JP2012516885A (ja) | 2009-02-04 | 2012-07-26 | ファイザー・インク | ４−アミノ−７，８−ジヒドロピリド［４，３−ｄ］ピリミジン−５（６Ｈ）−オン誘導体 |
| JP2013526544A (ja) | 2010-05-12 | 2013-06-24 | ヴァンダービルト ユニバーシティー | 複素環スルホンｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 |
| PH12013500301A1 (en) | 2010-08-16 | 2013-03-25 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
| US8580829B2 (en) | 2010-08-26 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| EA201300389A1 (ru) | 2010-09-23 | 2013-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Оксадиазольные ингибиторы продуцирования лейкотриена |
| WO2012040137A1 (en) * | 2010-09-23 | 2012-03-29 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
-
2013
- 2013-01-30 AR ARP130100282A patent/AR089853A1/es unknown
- 2013-01-31 EP EP13702219.0A patent/EP2809321B1/en active Active
- 2013-01-31 US US13/755,351 patent/US9248187B2/en active Active
- 2013-01-31 JP JP2014555197A patent/JP6069771B2/ja active Active
- 2013-01-31 WO PCT/EP2013/051871 patent/WO2013113799A1/en not_active Ceased
- 2013-01-31 UY UY0001034604A patent/UY34604A/es unknown
- 2013-01-31 TW TW102103835A patent/TW201343641A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505550A5 (enExample) | ||
| RU2015104537A (ru) | Способы лечения стромальных опухолей желудочно-кишечного тракта | |
| RU2011117059A (ru) | Применение антагонистов smoothened для лечения связанных с путем hedgehog нарушений | |
| RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| JP2016526540A5 (enExample) | ||
| AU2014310371A1 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| RU2008138649A (ru) | Применение а1-агонистов аденозина и/или двойных а1/а2в-агонистов аденозина для получения лекарственных средств для лечения заболеваний | |
| JP2013520443A5 (enExample) | ||
| RU2004139029A (ru) | Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний | |
| JP2006514611A5 (enExample) | ||
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| JP2013518036A5 (enExample) | ||
| GB201121503D0 (en) | Medicament delivery technology | |
| JP2008526861A5 (enExample) | ||
| RU2019112148A (ru) | Фармацевтическая композиция и способ лечения неалкогольной жировой болезни печени | |
| RU2012146874A (ru) | Производные пиразолопиридина | |
| JP2014521738A5 (enExample) | ||
| JP5765738B2 (ja) | ロスバスタチンおよびアトルバスタチン誘導体 | |
| US20110207710A1 (en) | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies | |
| RU2016111390A (ru) | Неконкурентные антагонисты никотиновых рецепторов | |
| US20100204249A1 (en) | Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia | |
| JP2012505225A5 (enExample) | ||
| CN101193656B (zh) | 甘油三酸酯降低剂 | |
| JP2005522490A5 (enExample) | ||
| RU2006116463A (ru) | Ингибиторы глутаминфруктозо-6-фосфатамидотрансферазы |